Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax (2021 - 2026)

Ironwood Pharmaceuticals has disclosed Long-Term Deferred Tax across 6 years of filings, most recently posting $84.2 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $84.2 million, down 41.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.2 million (down 41.32% YoY), and the FY2025 annual result was $103.4 million, down 28.29% from the prior year.
• Long-Term Deferred Tax came in at $84.2 million for Q1 2026 at Ironwood Pharmaceuticals, down from $103.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $335.4 million in Q1 2022 to a low of $84.2 million in Q1 2026.
• The 5-year median for Long-Term Deferred Tax is $206.3 million (2024), against an average of $206.9 million.
• Across the five-year window, Long-Term Deferred Tax slipped 5.11% in 2022 and tumbled 45.13% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Long-Term Deferred Tax stood at $283.7 million in 2022, then dropped by 25.15% to $212.3 million in 2023, then tumbled by 32.07% to $144.2 million in 2024, then dropped by 28.29% to $103.4 million in 2025, then declined by 18.56% to $84.2 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $84.2 million (Q1 2026), $103.4 million (Q4 2025), and $101.7 million (Q3 2025), per Business Quant data.